Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-75 vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily metabolized via CYP3A4 in the liver and intestinal mucosa to norfentanyl and other minor metabolites; undergoes extensive first-pass metabolism.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
90-95% bound to alpha-1-acid glycoprotein and albumin
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
6-7 L/kg, indicating extensive tissue distribution
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Fentanyl transdermal: 50-65% of patch content absorbed into systemic circulation
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Reduce dose by 50% and monitor.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50%. Class C: Avoid use.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Children ≥2 years: 12.5-25 mcg/hr initial, titrate based on need; max dose 25 mcg/hr for opioid-naive.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initial dose reduction of 25-50%; titrate cautiously; avoid in frail elderly.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of respiratory depression that may result in death; ensure proper patient selection, dosing, and monitoring. Avoid use in opioid non-tolerant patients. Accidental exposure can be fatal. Concomitant use with CNS depressants increases risk. Risk of abuse, misuse, addiction, and diversion. Neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of life-threatening respiratory depression from CYP3A4 inhibitors or discontinuation of CYP3A4 inducers.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of life-threatening respiratory depression, especially in elderly, cachectic, or debilitated patients,Risk of opioid-induced hyperalgesia,Risk of serotonin syndrome with serotonergic drugs,Hypersensitivity reactions including anaphylaxis,Risk of withdrawal with abrupt discontinuation,Hepatic or renal impairment may alter pharmacokinetics,Avoid in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected paralytic ileus,May impair mental or physical abilities needed for driving or operating machinery,Use with caution in patients with head injuries, increased intracranial pressure, or convulsive disorders,Application site reactions or adhesive-related injuries
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Opioid non-tolerant patients (not established for acute pain or short-term use),Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to fentanyl or any component of the system (e.g., adhesives),Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No significant food interactions. Grapefruit juice may increase fentanyl levels via CYP3A4 inhibition; caution with high intake. Avoid alcohol due to additive CNS depression.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS) postpartum. Use during labor may cause respiratory depression in neonate. Risk of preterm birth and low birth weight with prolonged use.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Fentanyl is excreted in breast milk. M/P ratio approximately 0.4. Breastfeeding is generally not recommended during Duragesic-75 use due to risk of infant sedation and respiratory depression. If used, monitor infant for unusual sleepiness, difficulty breathing, or poor feeding. Alternative analgesics are preferred.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustments are established for Duragesic-75 in pregnancy. Fentanyl pharmacokinetics may be altered due to increased plasma volume, renal clearance, and hepatic metabolism; however, transdermal absorption may be inconsistent. Use lowest effective dose for shortest duration. Consider alternative opioids with more pregnancy data. Taper dose before delivery to reduce NAS risk.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
DURAGESIC-75 delivers fentanyl at 75 mcg/hour transdermally. Do not use in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-hairy skin on upper torso or upper arm. Avoid heat sources (heating pads, hot tubs) as heat increases absorption. Onset ~12-24 hours; peak effect ~24-72 hours. Remove old patch before applying new; rotate sites. Do not cut or damage the patch. Monitor for serotonin syndrome if used with serotonergic drugs. For breakthrough pain, use immediate-release opioids not additional fentanyl patches.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Apply the patch to a flat, non-hairy area of the upper body or arm. Do not use on skin that is irritated, cut, or scarred.,Do not expose the patch to direct heat sources like heating pads, electric blankets, hot tubs, or sunbathing—this can cause a dangerous overdose.,Wash hands after handling the patch. Dispose of used patches by folding sticky sides together and flushing down toilet per FDA guidelines.,Remove the old patch and apply the new patch to a different skin site every 72 hours (3 days). Rotate sites to avoid skin irritation.,Do not cut, chew, or damage the patch—this can lead to rapid release of fentanyl and fatal overdose.,Store patches in a secure place away from children and pets. Accidental exposure can be fatal.,Common side effects include nausea, vomiting, constipation, dizziness, and drowsiness. Report severe drowsiness, confusion, difficulty breathing, or signs of an allergic reaction.,Avoid alcohol, other opioids, benzodiazepines, and sedatives as they increase risk of respiratory depression.,Do not stop using this medication suddenly; taper with prescriber to avoid withdrawal symptoms.,Seek emergency care for symptoms of overdose: slow or shallow breathing, extreme drowsiness, or unresponsiveness.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-75 vs ACTIQ, answered by our medical review team.
DURAGESIC-75 is a Opioid Analgesic that works by Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-75 and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-75 is: Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-75 and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-75 is classified as Category C. Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may . ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.